Prophylactic Tranexamic Acid Reduces Postpartum Hemorrhage

Launched by RENJI HOSPITAL · Dec 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called tranexamic acid (TXA) to help prevent a serious condition known as postpartum hemorrhage (PPH) in women who have certain autoimmune diseases. Postpartum hemorrhage is when a woman loses a lot of blood after giving birth, especially after a cesarean delivery (C-section). This trial specifically focuses on women with systemic autoimmune diseases, like lupus or rheumatoid arthritis, as they are at higher risk for PPH. The goal is to see if TXA can safely reduce blood loss and improve outcomes for both mothers and their babies.

To be eligible for this study, participants must be female, planning to have a C-section, and diagnosed with a systemic autoimmune disease. They must also agree to participate by signing an informed consent form. Women with certain health issues, like severe kidney problems or a history of blood clots, will not be able to join the trial. Participants can expect to receive TXA during their C-section and will be monitored for any side effects and overall health during recovery. This research aims to provide valuable information that could help improve care for pregnant women with autoimmune conditions in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients undergoing cesarean delivery
• • 2. Preoperative diagnosis of pregnancy with systemic autoimmune diseases (systemic lupus erythematosus, antiphospholipid syndrome, systemic sclerosis, Sjogren's syndrome, rheumatoid arthritis, undifferentiated connective tissue disease)
• • 3. Obtain informed consent.
• Exclusion Criteria:
• • 1. intrauterine fetal death
• • 2. Existing/previous history of thromboembolism
• • 3. Hemorrhagic disease, significant prenatal bleeding
• • 4. Balloon placement of internal iliac artery
• • 5. Allergic to tranexamic acid
• • 6. Severe renal insufficiency (serum creatinine \>451μmol/L or blood urea nitrogen \>20mmol/L)
• • 7. Epilepsy